NASDAQ:ALKSAlkermes Stock Price, Forecast & News

Alkermes' stock was trading at $16.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALKS stock has increased by 15.0% and is now trading at $18.68.
View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Alkermes.

Alkermes is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Alkermes.

Alkermes Plc (NASDAQ:ALKS) posted its earnings results on Wednesday, July, 29th. The company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.19. The company had revenue of $247.53 million for the quarter, compared to the consensus estimate of $232.70 million. Alkermes had a negative net margin of 10.87% and a positive return on equity of 4.47%. The business's revenue for the quarter was down 11.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.09 EPS.
View Alkermes' earnings history.

Alkermes issued an update on its FY20 earnings guidance on Wednesday, July, 29th. The company provided EPS guidance of $0.00-0.19 for the period, compared to the Thomson Reuters consensus estimate of $0.11. The company issued revenue guidance of $965-1.005 billion, compared to the consensus revenue estimate of $983.05 million.

10 equities research analysts have issued twelve-month price objectives for Alkermes' stock. Their forecasts range from $15.00 to $28.00. On average, they expect Alkermes' stock price to reach $19.80 in the next year. This suggests a possible upside of 6.0% from the stock's current price.
View analysts' price targets for Alkermes.

Media coverage about ALKS stock has been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alkermes earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Alkermes.

Alkermes saw a decline in short interest during the month of July. As of July 15th, there was short interest totaling 10,500,000 shares, a decline of 11.9% from the June 30th total of 11,920,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is presently 6.6 days. Currently, 6.7% of the company's stock are short sold.
View Alkermes' Current Options Chain.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Starbucks (SBUX), Alibaba Group (BABA), Walt Disney (DIS), Johnson & Johnson (JNJ) and Pfizer (PFE).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (2.52%), UBS Group AG (1.24%), Meditor Group Ltd (0.47%), Rhenman & Partners Asset Management AB (0.20%), MERIAN GLOBAL INVESTORS UK Ltd (0.19%) and Hardman Johnston Global Advisors LLC (0.15%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops.
View institutional ownership trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd, and Rhenman & Partners Asset Management AB. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, Michael J Landine, and Richard F Pops.
View insider buying and selling activity for Alkermes.

ALKS stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, First Trust Advisors LP, MERIAN GLOBAL INVESTORS UK Ltd, Hardman Johnston Global Advisors LLC, Nisa Investment Advisors LLC, Profund Advisors LLC, Zurcher Kantonalbank Zurich Cantonalbank , and ProShare Advisors LLC.
View insider buying and selling activity for Alkermes.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $18.68.

Alkermes has a market capitalization of $2.97 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

The official website for Alkermes is www.alkermes.com.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]